These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21963476)

  • 1. Doxazosin-carrageenan interactions: a novel approach for studying drug-polymer interactions and relation to controlled drug release.
    Pavli M; Baumgartner S; Kos P; Kogej K
    Int J Pharm; 2011 Dec; 421(1):110-9. PubMed ID: 21963476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix tablets based on carrageenans with dual controlled release of doxazosin mesylate.
    Pavli M; Vrečer F; Baumgartner S
    Int J Pharm; 2010 Nov; 400(1-2):15-23. PubMed ID: 20727957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Release mechanism of doxazosin from carrageenan matrix tablets: Effect of ionic strength and addition of sodium dodecyl sulphate.
    Kos P; Pavli M; Baumgartner S; Kogej K
    Int J Pharm; 2017 Aug; 529(1-2):557-567. PubMed ID: 28648579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of biopolymers carrageenans with cationic drug doxazosin mesylate characterized by means of differential scanning calorimetry.
    Pavli M; Vrecer F; Baumgartner S
    Pharmazie; 2010 Jul; 65(7):525-6. PubMed ID: 20662324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of release characteristics of highly soluble drug trimetazidine hydrochloride from chitosan-carrageenan matrix tablets.
    Li L; Wang L; Shao Y; Tian Y; Li C; Li Y; Mao S
    J Pharm Sci; 2013 Aug; 102(8):2644-54. PubMed ID: 23754467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of density functional theory in combination with FTIR and DSC to characterise polymer drug interactions for the preparation of sustained release formulations between fluvastatin and carrageenans.
    Karavas E; Koutris E; Papadopoulos AG; Sigalas MP; Nanaki S; Papageorgiou GZ; Achilias DZ; Bikiaris DN
    Int J Pharm; 2014 May; 466(1-2):211-22. PubMed ID: 24613179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH-independent sustained release matrix tablet containing doxazosin mesylate: effect of citric acid.
    Cha KH; Tran TH; Kim MS; Kim JS; Park HJ; Park J; Cho W; Hwang SJ
    Arch Pharm Res; 2010 Dec; 33(12):2003-9. PubMed ID: 21191766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled-release tablet matrices from carrageenans: compression and dissolution studies.
    Hariharan M; Wheatley TA; Price JC
    Pharm Dev Technol; 1997 Nov; 2(4):383-93. PubMed ID: 9552467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro vs. canine data for assessing early exposure of doxazosin base and its mesylate salt.
    Erceg M; Vertzoni M; Cerić H; Dumić M; Cetina-Čižmek B; Reppas C
    Eur J Pharm Biopharm; 2012 Feb; 80(2):402-9. PubMed ID: 22019530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix tablets of carrageenans. II. Release behavior and effect of added cations.
    Picker KM
    Drug Dev Ind Pharm; 1999 Mar; 25(3):339-46. PubMed ID: 10071827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of nifedipine controlled release tablets prepared using mucoadhesive swellable polymer.
    Felician WA; Ghaly ES
    Pharm Dev Technol; 2011 Oct; 16(5):536-41. PubMed ID: 20954856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parameters affecting the drug release from in situ gelling nasal inserts.
    Bertram U; Bodmeier R
    Eur J Pharm Biopharm; 2006 Jul; 63(3):310-9. PubMed ID: 16513333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of sodium dodecyl sulfate on swelling, erosion and release behavior of HPMC matrix tablets containing a poorly water-soluble drug.
    Zeng A; Yuan B; Fu Q; Wang C; Zhao G
    Pharm Dev Technol; 2009; 14(5):499-505. PubMed ID: 19743948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of polyelectrolyte counterion specificity, charge density, and conformation on polyelectrolyte-amphiphile interaction: the carrageenan/furcellaran-amitriptyline system.
    Hugerth A; Sundelöf LO
    Biopolymers; 2001 Feb; 58(2):186-94. PubMed ID: 11093117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the swelling behaviour of iota-carrageenan in monolithic matrix tablets.
    Kelemen A; Buchholcz G; Sovány T; Pintye-Hódi K
    J Pharm Biomed Anal; 2015 Aug; 112():85-8. PubMed ID: 25966465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug release from complexes with a series of poly(carboxyalkyl methacrylates), a new class of weak polyelectrolytes.
    Cornejo-Bravo JM; Flores-Guillen ME; Lugo-Medina E; Licea-Claverie A
    Int J Pharm; 2005 Nov; 305(1-2):52-60. PubMed ID: 16226001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: effect of formulation factors on dissolution rates.
    Nerurkar J; Jun HW; Price JC; Park MO
    Eur J Pharm Biopharm; 2005 Sep; 61(1-2):56-68. PubMed ID: 15893919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroretentive drug delivery systems with L-dopa based on carrageenans and hydroxypropylmethylcellulose.
    Dorożyński P; Kulinowski P; Mendyk A; Jachowicz R
    Int J Pharm; 2011 Feb; 404(1-2):169-75. PubMed ID: 21095225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled-release tablets from carrageenans: effect of formulation, storage and dissolution factors.
    Gupta VK; Hariharan M; Wheatley TA; Price JC
    Eur J Pharm Biopharm; 2001 May; 51(3):241-8. PubMed ID: 11343889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrophobic weak acid polymers as controlled release carriers.
    Cornejo-Bravo JM; Partida-Soria Y; Serrano-Medina A; Espinoza-Dueñas K; Ramos MA; Licea-Claverie A
    Pharm Dev Technol; 2012; 17(2):170-6. PubMed ID: 21047274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.